(Q35854444)

10 August 2017

1 reference

title

Effectiveness of proton pump inhibitors in nonerosive reflux disease (English)

1 reference

10 August 2017

Bonnie B Dean

1

1 reference

10 August 2017

Anacleto D Gano

2

1 reference

10 August 2017

Kevin Knight

3

1 reference

10 August 2017

Joshua J Ofman

4

1 reference

10 August 2017

Ronnie Fass

5

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 August 2004

1 reference

Clinical Gastroenterology and Hepatology

10 August 2017

published in

1 reference

10 August 2017

volume

2

1 reference

10 August 2017

issue

8

1 reference

10 August 2017

page(s)

656-664

1 reference

Diagnosis of symptomatic gastroesophageal reflux disease

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900288-5

7 January 2021

Omeprazole in the long-term treatment of gastro-oesophageal reflux disease. A double-blind randomized dose-finding study

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900288-5

7 January 2021

Predictive factors of the long term outcome in gastro-oesophageal reflux disease: six year follow up of 107 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900288-5

7 January 2021

Clinical characteristics and natural history of symptomatic but not excess gastroesophageal reflux

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900288-5

7 January 2021

Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900288-5

7 January 2021

Epidemiology and pathophysiology of symptomatic gastroesophageal reflux disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900288-5

7 January 2021

Healing and relapse of severe peptic esophagitis after treatment with omeprazole

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900288-5

7 January 2021

Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900288-5

7 January 2021

Heartburn treatment in primary care: randomised, double blind study for 8 weeks

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900288-5

7 January 2021

Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900288-5

7 January 2021

Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900288-5

7 January 2021

Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900288-5

7 January 2021

Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled, dose-ranging study. USA Merck Gastroesophageal Reflux Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900288-5

7 January 2021

The effect of cisapride in maintaining symptomatic remission in patients with gastro-oesophageal reflux disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900288-5

7 January 2021

Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900288-5

7 January 2021

Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900288-5

7 January 2021

Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900288-5

7 January 2021

Treating the symptoms of gastro‐oesophageal reflux disease: a double‐blind comparison of omeprazole and cisapride

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900288-5

7 January 2021

Non-erosive reflux disease (NERD)--acid reflux and symptom patterns

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900288-5

7 January 2021

Asthma and gastroesophageal reflux: acid suppressive therapy improves asthma outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900288-5

7 January 2021

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900288-5

7 January 2021

10.1016/S1542-3565(04)00288-5

Identifiers

DOI

1 reference

10 August 2017

1 reference